1. Home
  2. Directory
  3. Nevada
  4. Las Vegas
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1053472449

MICHELLE A FONTENELLE-GILMER M.D.
Prescription History 1053472449
Psychiatry & Neurology - Child & Adolescent Psychiatry in Las Vegas, NV

NPI Status: Active since December 12, 2006

Contact Information

9440 W SAHARA AVE STE 237
LAS VEGAS, NV
ZIP 89117
Phone: (702) 765-4965

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MICHELLE A FONTENELLE-GILMER M.D., an active Child & Adolescent Psychiatry specialist practicing in Las Vegas, NV. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 91 documented patient claims. Among these therapy options, the most frequently utilized medication is Quetiapine Fumarate, which accounts for 32 claims alone.

Medication Index

A
C
M
Q
V
No matching medications currently found on file.

Alprazolam

Generic Formulation: AlprazolamSpecialty: Neuropsychiatry
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 570
NV State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills70.4
Peer Average Days Supply2,005
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.8% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $552.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$29.05

State Avg Cost Per Claim

$8.07

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238)

Therapeutic Applications

Alprazolam is used to treat anxiety and panic disorders. It belongs to a class of medications called benzodiazepines which act on the brain and nerves (central nervous system) to produce a calming effect. It works by enhancing the effects of a certain natural chemical in the body (GABA).

Clonazepam

Generic Formulation: ClonazepamSpecialty: Neuropsychiatry
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NV State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills44.7
Peer Average Days Supply1,283
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.7% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $93.00 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.75

State Avg Cost Per Claim

$7.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.

Therapeutic Applications

Clonazepam is used to prevent and control seizures. This medication is known as an anticonvulsant or antiepileptic drug. It is also used to treat panic attacks. Clonazepam works by calming your brain and nerves. It belongs to a class of drugs called benzodiazepines.

Mirtazapine

Generic Formulation: MirtazapineSpecialty: Neuropsychiatry
Provider Metrics Summary
Total Claims 15
30-Day Fills 17.0
Days Supply 494
NV State Average Benchmarks
Peer Average Claims39.0
Peer Average 30-Day Fills59.7
Peer Average Days Supply1,726
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.5% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $191.25 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.75

State Avg Cost Per Claim

$22.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.

Therapeutic Applications

Mirtazapine is used to treat depression. It improves mood and feelings of well-being. Mirtazapine is an antidepressant that works by restoring the balance of natural chemicals (neurotransmitters) in the brain.

Quetiapine Fumarate

Generic Formulation: Quetiapine FumarateSpecialty: Neuropsychiatry
Provider Metrics Summary
Total Claims 32
30-Day Fills 32.0
Days Supply 960
NV State Average Benchmarks
Peer Average Claims53.0
Peer Average 30-Day Fills75.5
Peer Average Days Supply2,182
Conservative Utilization

This provider writes prescriptions for this formulation 39.6% less frequently than the standard regional baseline metric for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $564.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$17.65

State Avg Cost Per Claim

$28.79

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A dibenzothiazepine and ANTIPSYCHOTIC AGENT that targets the SEROTONIN 5-HT2 RECEPTOR; HISTAMINE H1 RECEPTOR, adrenergic alpha1 and alpha2 receptors, as well as the DOPAMINE D1 RECEPTOR and DOPAMINE D2 RECEPTOR. It is used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER and DEPRESSIVE DISORDER.

Therapeutic Applications

This medication is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder, sudden episodes of mania or depression associated with bipolar disorder). Quetiapine is known as an anti-psychotic drug (atypical type). It works by helping to restore the balance of certain natural substances (neurotransmitters) in the brain. This medication can decrease hallucinations and improve your concentration. It helps you to think more clearly and positively about yourself, feel less nervous, and take a more active part in everyday life. It may also improve your mood, sleep, appetite, and energy level. Quetiapine can help prevent severe mood swings or decrease how often mood swings occur.

Venlafaxine Hcl Er

Generic Formulation: Venlafaxine HclSpecialty: Neuropsychiatry
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 390
NV State Average Benchmarks
Peer Average Claims28.0
Peer Average 30-Day Fills57.8
Peer Average Days Supply1,715
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 53.6% less volume than the regional standard for practitioners inside NV. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $394.72 across this reporting matrix range.

Provider Avg Cost Per Claim

$30.36

State Avg Cost Per Claim

$29.00

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Venlafaxine is used to treat depression, anxiety, panic attacks, and social anxiety disorder (social phobia). It may improve your mood and energy level and may help restore your interest in daily living. It may also decrease fear, anxiety, unwanted thoughts, and the number of panic attacks. Venlafaxine is known as a serotonin-norepinephrine reuptake inhibitor (SNRI). It works by helping to restore the balance of certain natural substances (serotonin and norepinephrine) in the brain.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MICHELLE A FONTENELLE-GILMER M.D. provides transparency into local medical care patterns within Las Vegas, NV.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Child & Adolescent Psychiatry** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.